Telos rx does not currently offer 5-Amino-1MQ for compounding. This article lays out, honestly and without a timeline, what would actually need to happen before that could change.
What to know: availability depends on independent factors, including stronger human research, clearer regulatory footing for compounding, and reliable pharmacy sourcing. None of these has a confirmed date. Telos rx will not describe 5-Amino-1MQ using any language implying imminent arrival, only as currently under review.
What "not currently offered" means today
5-Amino-1MQ is a small molecule studied for its activity against an enzyme called NNMT, found in fat and liver tissue. It is not a classic peptide chain, even though it is often grouped with peptides in wellness discussion.
Telos rx has not added it to its clinical program. That is a statement about where telos rx's own review currently stands, not a prediction about the future. You can read more about telos rx's current status on 5-Amino-1MQ.
The first requirement: a stronger human evidence base
Most published research on 5-Amino-1MQ and NNMT inhibition comes from cell culture and animal studies. Large, well-designed human trials are not part of the current public research record for this compound.
Before telos rx would consider adding 5-Amino-1MQ to its program, a meaningfully larger body of human evidence would need to exist. Preclinical promise is a starting point for research, not a basis for a clinical decision affecting real patients.
This is true of any substance telos rx evaluates. Evidence quality is the first filter, and it is independent of how popular a substance has become in online discussion.
Key takeaway: Availability depends on stronger human research, clearer regulatory footing, and reliable sourcing. Telos rx has no confirmed timeline for any of these.
The second requirement: clearer regulatory footing
In 2026, a regulatory advisory body reviewed several research peptides and issued non-binding recommendations. A non-binding recommendation is not a rule change, and it is not an approval for compounding pharmacies to prepare 5-Amino-1MQ.
For compounding to become straightforward, actual regulatory action would need to follow, whether that comes as clearer guidance, a formal rule change, or another concrete step. None of that has happened yet for this substance.
For general background on how compounded substances are regulated in the United States, see the FDA's overview of human drug compounding.
The third requirement: reliable pharmacy sourcing
Even with stronger evidence and clearer regulation, a compounding pharmacy needs a dependable, quality-controlled supply chain before it can responsibly prepare a substance for patients. That infrastructure does not appear overnight.
Telos rx works exclusively with partner compounding pharmacies, and it will not add a substance to its program based on sourcing it cannot verify for purity and consistency. This requirement is separate from the science and the regulation, and it has to be satisfied too.
Supply reliability is easy to overlook from outside the industry, but it is often the practical bottleneck even after the other pieces fall into place.
The fourth requirement: telos rx's own internal review
Even if the first three conditions were met, telos rx would still complete its own internal evaluation before adding 5-Amino-1MQ to its program. That review considers the evidence, the regulatory picture, sourcing, and how the substance would fit alongside what telos rx already offers.
This step exists on purpose. A substance clearing a regulatory bar elsewhere does not automatically mean telos rx will offer it immediately, or at all. Each addition to the program is a deliberate decision.
Patients sometimes assume regulatory change and product availability happen on the same day. In practice, there is nearly always a gap between the two.
Why telos rx will not give you a date
Every one of the four requirements above depends on people and processes outside telos rx's control. Researchers decide what to study and when to publish. Regulators decide their own timelines. Suppliers decide their own manufacturing schedules.
Because of that, any specific date telos rx offered would be a guess dressed up as information. Telos rx would rather tell you honestly that it does not know than offer a number that sounds reassuring but is not grounded in anything real.
If telos rx's position changes, the 5-Amino-1MQ page and articles like this one will be updated to reflect it.
What would not be enough on its own
It is worth being clear about what does not, by itself, change availability. Growing popularity in online wellness communities does not. A single new animal study does not. A seller's marketing claims do not, regardless of how confident they sound.
None of these substitutes for the actual requirements above. Telos rx's decision-making is deliberately insulated from trends and sales pressure, since the goal is a program built on evidence and reliable sourcing, not on what is currently popular to discuss.
This is also why an article like this one avoids projecting excitement about an uncertain future. The honest picture is more useful than an optimistic one that might not hold up.
How this compares to substances telos rx does offer
It helps to see the contrast. BPC-157, PT-141, NAD+ nasal spray, and sermorelin all cleared telos rx's internal review. Each has an established compounding pathway through partner pharmacies, and each is supported by a body of research and clinical use that telos rx found sufficient to build a program around.
5-Amino-1MQ has not cleared that same bar yet. That does not mean it never will at some future point. It means the requirements described above have not all been satisfied, and telos rx is not willing to guess about when, or whether, they might be.
Every substance telos rx eventually adds to its program goes through the same four-part process. Nothing skips the line because of demand or online attention, no matter how large or vocal that attention becomes across wellness communities.
How patients can track genuine progress
If you want a realistic way to monitor whether anything is changing, watch for two concrete signals rather than vague online buzz. The first is peer-reviewed human research actually being published, not just announced or previewed on social media.
The second is confirmed regulatory action, such as a rule change or formal guidance from an agency, rather than a non-binding recommendation. Both signals are publicly verifiable, unlike marketing claims from sellers with a financial stake in the outcome.
Absent both signals, treat any claim that availability is close as unsupported, regardless of how confidently it is stated.
It is also reasonable to ask a compounding pharmacy or telehealth provider directly whether they have information about a substance's regulatory status. A direct answer from a licensed source is more reliable than an anonymous forum post repeating a rumor as though it were confirmed news.
Setting a periodic reminder to check back, rather than searching daily, is a practical way to stay informed without the process becoming a source of ongoing frustration while nothing changes. Checking monthly or quarterly is usually enough, since regulatory and research timelines rarely move faster than that.
What you can reasonably do in the meantime
If 5-Amino-1MQ genuinely interests you, following peer-reviewed research as it publishes is a reasonable way to stay informed. Checking telos rx's own program pages periodically is another, since they are updated as telos rx's own status changes.
What is not reasonable, from a safety standpoint, is sourcing the substance from an unregulated seller in the meantime. Telos rx cannot vouch for the purity or accuracy of anything obtained outside its own partner pharmacy network. For general background on how weight and metabolism-related medications are evaluated, see the NIH NIDDK overview of prescription weight-management medication.
Which is right for you
Your underlying interest may be metabolic health or energy support rather than 5-Amino-1MQ specifically. NAD+ nasal spray is a compounded option telos rx currently offers, as low as $116 a month, rather than waiting on an uncertain future.
Telos rx also currently offers BPC-157, PT-141, and sermorelin, each compounded, not FDA-approved, and available through an asynchronous intake.
If NAD+ nasal spray fits your goals, start an online visit to find out if it is appropriate for you, subject to medical approval by a licensed provider.
Frequently Asked Questions
What would need to happen for telos rx to offer 5-Amino-1MQ?
Four things: a stronger human research base, clearer regulatory footing for compounding, reliable pharmacy sourcing, and telos rx's own internal review. None currently has a confirmed timeline.
Did the 2026 peptide review approve 5-Amino-1MQ?
No. That review produced non-binding recommendations, not an approval. Telos rx has not added the substance to its program as a result.
Why won't telos rx give a date for when it might be available?
Because the process depends on researchers, regulators, and suppliers, none of whom telos rx controls. A specific date would be a guess, not real information.
Does growing online popularity make availability more likely?
Not by itself. Telos rx's decisions are based on evidence, regulation, and sourcing, not on how widely a substance is discussed online.
Is it safe to buy 5-Amino-1MQ elsewhere while waiting?
Telos rx cannot vouch for outside sellers. Products sold that way are typically not intended for human consumption and are not prepared under pharmacy oversight.
What can I start with telos rx today instead?
Telos rx currently offers BPC-157, PT-141, NAD+ nasal spray, and sermorelin, each available through an asynchronous intake reviewed by a licensed provider.
This article is general information, not medical advice, and does not replace guidance from your own provider. Compounded medications are not FDA-approved. Telos rx works with partner compounding pharmacies that are LegitScript-certified.
5-Amino-1MQ is not currently offered by telos rx.